ARTICLE | Company News
AZ prices Tagrisso
November 18, 2015 2:02 AM UTC
AstraZeneca plc (LSE:AZN; NYSE:AZN) priced non-small cell lung cancer (NSCLC) drug Tagrisso osimertinib ( AZD9291) at a wholesale acquisition cost (WAC) of $12,750 per month.
AZ spokesperson Michele Meixell said AZ's patient assistance program would aim to limit co-pays to $25 per month for eligible patients. ...